DNA Damage Response Signaling: ATM/ATR Kinases, Checkpoint Enforcement, and PARP Inhibitor Mechanisms

# DNA Damage Response: ATM/ATR Kinase Activation, Checkpoint Enforcement, and DSB Repair Pathway Choice

For Research Use Only. Not for human or animal therapeutic use.

---

Introduction: Genome Surveillance as a Survival Imperative

Every cell in a replicating organism sustains tens of thousands of DNA lesions per day from endogenous sources (reactive oxygen species from mitochondrial respiration, hydrolytic depurination, replication errors, topoisomerase-mediated strand breaks) and exogenous insults (ultraviolet radiation, ionizing radiation, genotoxic chemicals). To survive, cells have evolved a sophisticated DNA damage response (DDR) network that detects lesions, amplifies the damage signal across the nucleus, enforces cell cycle checkpoints to prevent replication or mitosis with damaged DNA, and coordinates the appropriate repair pathway.

The DDR integrates three conceptually distinct functions: sensing (structural recognition of damaged DNA), signaling (kinase-mediated amplification and broadcasting of the damage signal), and effector responses (checkpoint enforcement, repair, apoptosis, or senescence). The two apical DDR kinases — ATM (Ataxia Telangiectasia Mutated) and ATR (ATM and Rad3-Related) — sit at the apex of the signaling cascade, phosphorylating hundreds of substrates on the consensus motif S/T-Q within minutes to hours of DNA damage.

Failure of DDR fidelity is a hallmark of cancer: mutations in TP53, BRCA1, BRCA2, ATM, CHEK2, and MLH1/MSH2 (mismatch repair) collectively account for a large fraction of hereditary cancer predisposition. Conversely, the DDR signaling machinery is an increasingly important pharmacological target: PARP inhibitors (olaparib, rucaparib, niraparib) exploit synthetic lethality with BRCA1/2 deficiency; ATR inhibitors (AZD6738, BAY1895344) target replication-stressed cancer cells; WEE1 inhibitors (AZD1775/adavosertib) force premature mitosis in checkpoint-deficient tumors.

This article covers the molecular mechanisms of DSB detection, ATM and ATR kinase activation, downstream checkpoint enforcement by CHK1/CHK2, the competing repair pathways of homologous recombination (HR) and non-homologous end joining (NHEJ), PARP1 biology, and the research tools that enable precise study of each DDR node.

---

DNA Double-Strand Break Detection

γH2AX: The Universal DSB Marker

The histone variant H2AX (encoded by H2AFX) is the most sensitive and universal marker of DNA double-strand breaks (DSBs). Within seconds to minutes of DSB formation, ATM (and to a lesser extent DNA-PKcs) phosphorylates H2AX at serine 139 (generating γH2AX) in a 1–2 Mb chromatin domain flanking the break. This γH2AX domain serves as a platform for DDR factor assembly and amplification.

γH2AX detection:

• •Immunofluorescence (IF): Anti-γH2AX antibody (clone JBW301, Millipore; or Cell Signaling #9718) produces discrete nuclear foci; each focus corresponds to approximately one DSB; number of foci per cell ≈ DSB burden; foci resolve as repair completes (kinetics: γH2AX foci peak 30–60 min post-IR, decline over 4–24 h)
• •Western blot: γH2AX band at ~15 kDa (H2AX + phosphate) above H2AX (~14 kDa); total signal ∝ DSB burden
• •Flow cytometry: Intracellular γH2AX staining enables cell cycle-resolved DSB measurement (combine with DAPI/PI for DNA content)

MDC1 (Mediator of DNA Damage Checkpoint 1): Directly binds γH2AX via its C-terminal BRCT domain; MDC1 then recruits additional ATM molecules and RNF8/RNF168 E3 ligases that ubiquitinate H2A at K13/K15, creating a secondary ubiquitin-dependent scaffold for 53BP1 and BRCA1 complex recruitment.

The MRN Complex: DSB Sensor and ATM Activator

The MRN (MRE11-RAD50-NBS1) complex is the primary DSB sensor and ATM activator:

• •MRE11: Nuclease (3'→5' exonuclease + endonuclease); tethers DNA ends; creates 3' ssDNA overhangs for HR; ATP hydrolysis drives nucleolytic processing
• •RAD50: ATPase with extended coiled-coil "arms" that bridge DNA ends; zinc hook dimerization at the tip enables inter-molecular tethering of sister chromatids or broken ends
• •NBS1 (Nibrin/p95): Adaptor; FHA and BRCT domains bind MDC1 and phosphorylated ATM substrates; C-terminal ATM-interaction motif directly binds and activates ATM

ATM activation by MRN: ATM normally exists as an inactive homodimer with the kinase domain blocked by the FATC domain of the partner. MRN binding to DSB ends recruits ATM to chromatin, and NBS1 directly contacts the ATM FATC region, promoting monomerization and autophosphorylation at S1981 (a marker of ATM activation used in research). ATM is also activated by chromatin changes (histone acetylation by TIP60/KAT5, which acetylates ATM at K3016) independent of direct DSB sensing.

---

ATM: Master Kinase for DSB Response

ATM Structure and Activation

ATM (~350 kDa) is a member of the PI3K-related kinase (PIKK) family along with ATR and DNA-PKcs. All PIKKs share a conserved C-terminal kinase domain flanked by FAT (FRAP-ATM-TRRAP) and FATC domains; the kinase domain uses the same DFG motif and activation loop as PI3Ks but phosphorylates protein (not lipid) substrates on S/T-Q motifs.

ATM substrate consensus: S/T-Q (serine or threonine followed by glutamine); ATM efficiently phosphorylates substrates with basic residues at −3/−4 (optimal: K/R-x-x-S/T-Q). The PIKK substrate consensus is shared by ATM, ATR, and DNA-PKcs, making substrate identity typically determined by which kinase is activated in a given context rather than sequence specificity alone.

Key ATM substrates:

• •H2AX S139 (γH2AX): DSB marker; chromatin amplification scaffold
• •CHK2 T68: Activates CHK2 kinase (G1/S checkpoint effector)
• •p53 S15: Stabilizes p53 (reduces MDM2 affinity); also phosphorylated at S15 by ATR/DNA-PKcs
• •BRCA1 S1387/S1524: Recruits BRCA1 to DSBs; activates BRCA1 E3 ligase activity
• •NBS1 S343: Amplification of MRN signal
• •SMC1 S966: Cohesion and intra-S checkpoint
• •MDC1 T98, S168 (multiple): MDC1 BRCT recognition of γH2AX; amplification of γH2AX domain
• •KAP1/TRIM28 S824: Chromatin relaxation at heterochromatic DSBs (required for efficient repair of heterochromatic breaks)
• •RPA32 S33: Marks ssDNA-RPA at resected DSB ends

KU-55933: ATP-competitive ATM inhibitor (IC50 ~12.9 nM for ATM; >100-fold selectivity over ATR, DNA-PKcs); blocks ATM-dependent γH2AX formation after IR; abolishes ATM-dependent checkpoint activation; widely used research tool. AZD1390 is a more potent, CNS-penetrant ATM inhibitor for advanced research applications.

---

ATR: Replication Stress Sentinel

ATR Activation: RPA-ssDNA Platform

ATR (ATR, serine/threonine kinase) is essential for all replicating cells (ATR deletion is lethal in dividing cells) and responds primarily to replication stress — stalled replication forks, UV-induced pyrimidine dimers (processed by NER to generate ssDNA), and resected DSBs (ssDNA generated by MRN/CtIP-mediated resection exposes ssDNA that activates ATR).

ATR activation cascade:

1. Single-stranded DNA (ssDNA) accumulates (at stalled replication forks, UV-NER intermediates, or resected DSBs)

2. RPA (Replication Protein A heterotrimer: RPA70/RPA32/RPA14) coats ssDNA, coating ~30 nt per heterotrimer

3. RPA-ssDNA recruits ATRIP (ATR-Interacting Protein) directly; ATRIP-ATR co-localizes to RPA-ssDNA

4. RAD17-RFC complex (a modified clamp loader) loads the 9-1-1 (RAD9-HUS1-RAD1) clamp at the ssDNA-dsDNA junction

5. RAD9 C-terminal tail binds TOPBP1 (topoisomerase-binding protein 1)

6. TOPBP1 AAD (ATR-activating domain) directly contacts ATR and activates kinase activity ~10–20-fold above basal

ETAA1: An alternative ATR activator (independent of TOPBP1) discovered in 2016; also contains an ATR-activating domain and is constitutively RPA-bound; important for ATR activation at stalled replication forks.

Key ATR substrates:

• •CHK1 S317/S345: Primary ATR effector; activates G2/M and intra-S checkpoints
• •RPA32 S4/S8 (by DNA-PKcs) / S33 (by ATR): Marks ssDNA-RPA
• •H2AX S139: Also phosphorylated by ATR (at stalled forks)
• •RAD51 T309: Promotes RAD51-BRCA2 interaction for HR
• •FANCM S1045: Activates FA pathway in response to replication stress
• •TopBP1 S1138: Positive feedback amplification
• •WEE1 S642: Stabilizes WEE1 (prevents premature CDK1 activation)

VE-821: Potent, selective ATR inhibitor (IC50 ~26 nM for ATR; >100-fold over ATM, DNA-PKcs); blocks replication stress-induced CHK1 S317/S345 phosphorylation; sensitizes cells to replication-stressing agents (HU, aphidicolin, gemcitabine, UV); preferred research tool for ATR biology. AZD6738 (ceralasertib) is a clinical-grade ATR inhibitor used in cancer research models.

---

CHK1 and CHK2: Effector Kinases of the DNA Damage Checkpoint

CHK2: The ATM Effector

CHK2 (CHEK2; 60 kDa) is activated by ATM-mediated phosphorylation at T68, which creates a docking site for the FHA domain of another CHK2 molecule; this CHK2-CHK2 dimerization drives trans-autophosphorylation at T383/T387 in the activation loop, producing fully active CHK2 that dissociates into active monomers (Bhatt et al., 2000, PMID: 11114886 reference context).

CHK2 substrates:

• •CDC25A S123/S178: Phosphorylation targets CDC25A for β-TrCP/SCF-mediated ubiquitination and degradation; loss of CDC25A prevents CDK2 activation → S-phase arrest
• •CDC25C S216: Generates 14-3-3 binding site → cytoplasmic sequestration → prevents CDK1/cyclin B activation → G2/M arrest
• •p53 S20: Inhibits MDM2-p53 interaction; stabilizes p53
• •BRCA1 S988: Promotes BRCA1 release from BARD1, facilitating BRCA1 nuclear foci formation
• •PML S117: Promotes p53 sumoylation and activation in PML nuclear bodies

CHK1: The ATR Effector and Replication Fork Protector

CHK1 (CHEK1; 54 kDa) is phosphorylated by ATR at S317 and S345; this does not directly activate CHK1 but promotes CHK1 release from chromatin (where it is constitutively tethered via its C-terminal regulatory domain interacting with Claspin) into the nucleoplasm where it can phosphorylate substrates. Full CHK1 activation requires Claspin (a co-activator that bridges CHK1-ATR interaction) and TIMELESS/TIPIN.

CHK1 substrates:

• •CDC25A S76: Degradation → CDK2 inhibition → S-phase and G2 arrest
• •CDC25B S323: 14-3-3 binding → cytoplasmic sequestration → G2/M arrest
• •CDC25C S216 (shared with CHK2)
• •WEE1 S642: Stabilizes WEE1 (CDK1 inhibitory kinase) → maintains CDK1-pY15 → G2 arrest
• •RAD51 T309: Promotes HR repair at stalled forks
• •FANCM S1045: ATR-CHK1-FANCM axis at ICLs

CHK1 inhibitors: UCN-01 (7-hydroxystaurosporine; first CHK1 inhibitor used in research; non-selective); AZD7762: ATP-competitive CHK1/CHK2 dual inhibitor (IC50 ~5 nM CHK1); PF-00477736: Selective CHK1 inhibitor (IC50 ~0.49 nM); LY2603618/rabusertib: CHK1 inhibitor used to force mitotic entry in checkpoint-defective research models; SB-218078 and CHIR-124: alternative CHK1 tools. CHK1 inhibitors are primarily studied for their ability to abrogate the G2 checkpoint and force p53-deficient cells into catastrophic mitosis.

---

Cell Cycle Checkpoint Mechanisms

G1/S Checkpoint (p53-Dependent)

The G1/S checkpoint prevents cells with DSBs from initiating DNA replication. It operates via two mechanisms with different kinetics:

Rapid (minutes to hours): CHK2-mediated CDC25A phosphorylation → CDC25A degradation → CDK2-pT160/pY15 (unactivated because CDC25A cannot remove CDK2 inhibitory phosphorylation Y15) → CDK2 inactive → no loading of MCM helicase and origin firing

Sustained (hours to days): ATM/CHK2-mediated p53 stabilization (S15/S20 phosphorylation → MDM2 dissociation) → p53 transcriptional activation of CDKN1A (p21) → p21 binds and inhibits CDK2/cyclin E and CDK4/6/cyclin D complexes → sustained G1 arrest; also GADD45A, 14-3-3σ, MDM2 (feedback)

Intra-S Checkpoint

Slows DNA replication in the presence of damage by inhibiting late-origin firing via CHK1-mediated CDC25A degradation (reduces CDK2 activity below threshold for new origin firing) and by promoting fork stability and restart.

G2/M Checkpoint

Prevents mitosis with unrepaired DSBs. CHK1/CHK2 phosphorylate CDC25B (S323) and CDC25C (S216), sequestering them on 14-3-3 proteins. Without active CDC25B/C, CDK1 remains inhibited at Y15 by WEE1/MYT1. Additionally, WEE1 is stabilized by CHK1 (S642) and ATR. CDK1-pY15 cannot associate with cyclin B1 at centrosomes → mitotic entry blocked.

WEE1 inhibitors: AZD1775 (adavosertib; WEE1 ATP-competitive inhibitor, IC50 ~5 nM); forces CDK1 activation in cells with active G2 checkpoint → premature mitotic entry → mitotic catastrophe in cells with unrepaired DNA; profound synthetic lethality with p53 mutation (p53-null cells rely entirely on the G2/M checkpoint); major research tool for checkpoint biology and cancer sensitization research.

---

DSB Repair Pathway Choice: HR vs. NHEJ

Non-Homologous End Joining (NHEJ)

NHEJ is the predominant DSB repair pathway in mammalian cells, active throughout the cell cycle but dominant in G1 phase. It joins broken DNA ends without requiring a homologous template:

Core NHEJ factors:

• •KU70/KU80 (XRCC6/XRCC5): Heterodimer; ring-shaped structure that threads onto and slides down from DSB ends; high affinity for dsDNA ends (Kd ~1 nM); recruits DNA-PKcs
• •DNA-PKcs (PRKDC): ~470 kDa PIKK kinase; catalytic subunit; autophosphorylates at S2056 cluster (T2609, S2056) upon KU-mediated DSB recruitment; autophosphorylation promotes conformational change and end-processing
• •Artemis (DCLRE1C): DNA nuclease; endonucleolytic activity activated by DNA-PKcs phosphorylation; cleaves hairpin ends and 3'/5' overhangs to create ligatable ends
• •DNA Pol μ/λ (POLM/POLL): Template-independent and template-dependent polymerases that fill gaps at NHEJ junctions
• •XRCC4-LIG4-XLF: Ligation complex; XRCC4 stimulates LIG4 ligase activity; XLF (Cernunnos) stimulates XRCC4-LIG4 activity on non-complementary ends; PAXX provides additional stimulation
• •DNA-PKcs inhibitors: NU7441 (IC50 ~14 nM DNA-PKcs; selective); M3814/peposertib (clinical-grade DNA-PKcs inhibitor, IC50 ~3 nM); KU-57788 (alternative research tool)

Homologous Recombination (HR)

HR is error-free repair using the sister chromatid as a template; restricted to S/G2 phase (when sister chromatid is available). HR initiation requires DSB resection to generate 3' ssDNA tails:

Resection:

1. Short-range resection: MRE11 nuclease (with CtIP/RBBP8 as activator, itself activated by CDK2-mediated phosphorylation at S327) nicks the DNA strand ≤300 bp from the break

2. Long-range resection: EXO1 (5'→3' exonuclease) or BLM-DNA2 helicase-nuclease extends tracts to >1,000 nt; generates extended 3' ssDNA overhangs

3. RPA coats 3' ssDNA (blocks secondary structures, activates ATR)

4. BRCA2 (with PALB2 mediator and BRCA1) loads RAD51 onto RPA-coated ssDNA (RAD51 displaces RPA); RAD51 forms nucleoprotein filament (ATP-dependent)

5. RAD51 filament performs strand invasion into homologous sequence on sister chromatid

6. DNA synthesis from the 3' invading end (by Pol δ/η) copies the template

7. Resolution of Holliday junctions (by BLM-TOP3α-RMI1/2 dissolution or GEN1/SLX1-SLX4 nucleolytic resolution)

Key HR factors:

• •BRCA1: BRCT domains bind phosphorylated proteins at DSBs; promotes resection and RAD51 loading; tumor suppressor; BRCA1 mutation → HR deficiency → PARP inhibitor sensitivity
• •BRCA2: BRC repeats (8×) bind RAD51 monomers; delivers RAD51 to ssDNA; mediates strand exchange; C-terminal domain binds DSS1
• •PALB2: Bridges BRCA1-BRCA2 at the break; required for BRCA2 nuclear localization
• •RAD51: RecA homolog; forms 3'–5' nucleoprotein filament; ADP-to-ATP exchange rate-limiting; B02 compound inhibits RAD51-ATPase and strand exchange (research tool)
• •RAD54: SNF2 translocase; stimulates RAD51 filament activity and promotes D-loop formation

The HR/NHEJ Switch: 53BP1 vs. BRCA1

The choice between HR and NHEJ is largely determined by competition between 53BP1 (promoting NHEJ) and BRCA1 (promoting HR):

53BP1 (TP53BP1): Binds H4K20me2 (constitutive histone mark) at DSBs via its tandem tudor domain; activated by RIF1 and PTIP effectors; blocks DSB resection and promotes NHEJ. Also promotes long-range chromosomal movements required for V(D)J and class switch recombination.

BRCA1: Antagonizes 53BP1 via CtIP activation and RAD51 loading; BRCA1 BRCT domain binds Abraxas/RAP80/MERIT40 complex that specifically recognizes K63-Ub + K13/K15-Ub (generated by RNF8/RNF168) at DSBs.

Cell cycle regulation of the switch: CDK activity rises in S/G2, phosphorylating CtIP S327 (activating resection) and BRCA1 S1524 (ATM-mediated), promoting HR. In G1, low CDK activity leaves CtIP inactive and 53BP1-NHEJ pathway dominant.

---

PARP1: First Responder to Single-Strand Breaks

PARP1 Structure and Activation

PARP1 (Poly(ADP-ribose) polymerase 1, encoded by PARP1) is a 113 kDa nuclear protein that detects single-strand breaks (SSBs) and certain DSB structures. PARP1 contains:

• •N-terminal zinc finger domains (ZnF1/2/3): ZnF1/2 bind SSB termini; ZnF3 contacts bent DNA; ZnF1-2 interaction with the broken strand induces a conformational change that allosterically activates the C-terminal catalytic domain
• •BRCT domain: Protein-protein interaction
• •Catalytic domain: Contains NAD⁺-binding Rossmann fold; transfers ADP-ribose from NAD⁺ to glutamate/aspartate/serine residues on target proteins; PARP1 auto-PARylates itself extensively on its BRCT domain

PAR synthesis: PARP1 uses NAD⁺ to synthesize poly(ADP-ribose) (PAR) chains — polymers of ADP-ribose with linear and branched topology reaching >200 units. PAR on PARP1 and neighboring histones creates a negatively charged scaffold that:

1. Loosens chromatin at the break (electrostatic repulsion of histones)

2. Recruits repair factors via PAR-binding modules (PBZ domain: APLF; WWE domain: RNF146; macrodomain: Macro-H2A; OB fold: RPA32)

3. Recruits XRCC1-LIG3 for SSB repair (BER)

PAR is degraded by PARG (poly(ADP-ribose) glycohydrolase) and ADP-ribosyl hydrolase (ARH3), regenerating free ADP-ribose and NAD⁺.

PARP Inhibitors: Mechanism and Synthetic Lethality

PARP inhibitors (PARPi) compete with NAD⁺ for binding to the PARP1/2 catalytic domain, preventing PAR synthesis. However, their key mechanism in cancer research is not simply enzyme inhibition but PARP trapping: PARPi stabilize PARP1/2 on DNA at SSB sites, preventing release after catalysis. Trapped PARP-DNA complexes block replication forks → DSBs at forks → synthetic lethality in HR-deficient cells (BRCA1/2 mutant) that cannot repair these DSBs.

PARP inhibitors and trapping potency:

Synthetic lethality concept: BRCA1/2-deficient cells rely entirely on error-prone NHEJ to repair DSBs that would normally be fixed by HR. PARPi-induced trapped PARP complexes → replication-associated DSBs → accumulate in BRCA1/2-deficient cells → cell death. BRCA-proficient cells can use HR to repair these DSBs and survive. This mechanistic insight drives BRCAness biomarker research.

---

Research Tools Table

---

Experimental Protocols for Research Applications

Protocol 1: γH2AX Immunofluorescence Foci Assay

Objective: Quantify DSB burden and repair kinetics in irradiated or drug-treated cells using γH2AX nuclear foci.

Materials: Ionizing radiation source (X-ray or ⁶⁰Co γ-ray; or etoposide 10 µM as chemical DSB inducer), anti-γH2AX antibody (Millipore clone JBW301, 1:500 dilution), Alexa Fluor 488 anti-mouse secondary, DAPI, 4% PFA/PBS fixative, 96-well optical plate or glass coverslips.

Procedure:

1. Seed cells on optical-bottom 96-well plate or glass coverslips; allow 24 h attachment

2. Irradiate (0, 1, 2, 4 Gy) or treat with etoposide (10 µM, 1 h); harvest at 0.5, 1, 2, 4, 8, 24 h post-treatment

3. Fix with 4% PFA, 15 min RT; permeabilize with 0.5% Triton X-100, 10 min; block 3% BSA, 30 min

4. Anti-γH2AX (1:500) overnight at 4°C; Alexa Fluor 488 secondary + DAPI 1 h RT; image with 40× objective

5. Count foci per cell (ImageJ: DAPI mask for nuclei; find maxima in γH2AX channel per nucleus; automated with CellProfiler)

6. Plot: average foci per cell vs. time; dose-response at a fixed time (e.g., 1 h); resolution curves (foci at t = 0, 4, 8, 24 h)

Expected result: Unirradiated cells: 1–3 spontaneous γH2AX foci/cell; 2 Gy: ~50–80 foci/cell at 30 min (approximately equal to DSBs per Gy × 2); foci resolve to baseline by 8–24 h in repair-proficient cells; ATM inhibitor (KU-55933, 10 µM) added pre-IR abolishes γH2AX formation; NHEJ-deficient (KU80 knockdown) cells show persistent foci >24 h.

---

Protocol 2: DDR Signaling Cascade Western Blot Panel

Objective: Document activation of ATM, CHK1, CHK2, p53 signaling cascade after DSB induction.

Materials: Ionizing radiation or doxorubicin (500 nM, 1 h), antibodies: pATM S1981 (Cell Signaling #13050), pCHK2 T68 (Cell Signaling #2197), pCHK1 S345 (Cell Signaling #2341), p53 (Cell Signaling #2527), pp53 S15 (Cell Signaling #9284), pRPA32 S4/S8 (Bethyl A300-245A), γH2AX (Millipore 05-636), total CHK1/CHK2/p53 for normalization; ATM inhibitor KU-55933; ATR inhibitor VE-821.

Procedure:

1. Treat ± 10 µM KU-55933 (ATM inh) or 1 µM VE-821 (ATR inh), 30 min pre-treatment

2. Irradiate (5 Gy) or add doxorubicin; harvest at 0, 30, 60, 120, 240 min

3. Lyse in RIPA + phosphatase inhibitors; SDS-PAGE; probe phospho-antibodies; strip/reprobe totals

4. Assign each phospho-event to ATM vs. ATR: pCHK2-T68 and pATM-S1981 are ATM-specific; pCHK1-S345 is primarily ATR; pRPA32-S4/S8 is ATR/DNA-PKcs; pp53-S15 is shared ATM/ATR

Expected result: DSBs (IR): pATM S1981 and pCHK2 T68 appear within 15–30 min; pp53 S15 at 30–60 min; pCHK1 S345 may be weaker (ATR less dominant for pure DSBs). KU-55933 abolishes pATM S1981, pCHK2 T68, pp53 S15 after IR. VE-821 blocks pCHK1 S345 after hydroxyurea (replication stress) but has less effect on IR-induced pCHK2. Doxorubicin (DNA intercalator + Topo II): activates both ATM (DSBs) and ATR (replication forks), so both pCHK2 and pCHK1 are induced.

---

Protocol 3: HR Efficiency Assay — RAD51 Foci Quantification

Objective: Quantify HR capacity by measuring RAD51 nuclear foci formation after DSB induction.

Materials: Etoposide (10 µM, 1 h) or IR (5 Gy); anti-RAD51 (Abcam ab133534, 1:500), anti-γH2AX (co-stain for DSB load normalization), fluorescent secondaries, DAPI; EdU labeling kit (for S/G2 phase restriction).

Procedure:

1. Optional: label replicating cells with EdU (10 µM, 30 min) before damage to identify S-phase cells (where HR is predominant)

2. Treat with etoposide (10 µM, 1 h) then wash; allow 4 h recovery for RAD51 foci to form (RAD51 is loaded post-resection, peaks ~2–4 h after damage)

3. Fix with 4% PFA; permeabilize with 0.5% Triton X-100; block; co-stain anti-RAD51 + anti-γH2AX + DAPI ± Click-EdU (Alexa Fluor 647)

4. Count RAD51 foci per cell in EdU+ (S/G2) cells; calculate % cells with >5 RAD51 foci; also calculate RAD51 foci per γH2AX focus (HR efficiency ratio)

5. Compare: WT vs. BRCA1/2-KO (genetic control); WT ± BRCA2 siRNA; WT ± B02 RAD51 inhibitor

Expected result: WT S/G2 phase cells: 50–80% have >5 RAD51 foci at 4 h post-damage; BRCA2-KO/knockdown: <10% cells with RAD51 foci (RAD51 cannot be loaded without BRCA2); BRCA1-KO: reduced RAD51 foci (BRCA1 promotes resection required for RPA-ssDNA and RAD51 loading); B02 (RAD51 inhibitor, 20 µM): does not prevent RAD51 foci formation but blocks strand exchange in in vitro assays; G1-phase cells (EdU−, 2N DNA): very few RAD51 foci even in WT (validates S/G2 restriction of HR).

---

Protocol 4: PARP Trapping Assay — Chromatin Fractionation

Objective: Quantify PARP1 trapping at damaged chromatin by measuring PARP1 in chromatin-bound vs. soluble fractions after PARPi treatment.

Materials: Olaparib (10 µM) or talazoparib (1 µM), veliparib (10 µM, minimal trapping control), methyl methanesulfonate (MMS, 0.01%) to induce SSBs that trap PARP; chromatin fractionation: hypotonic lysis buffer + NP-40 → cytoplasmic; benzonase-treated chromatin fraction; anti-PARP1 (Cell Signaling #9542), anti-H3 (chromatin loading control), anti-GAPDH (cytoplasmic control).

Procedure:

1. Pre-treat cells with PARP inhibitor (olaparib/talazoparib/veliparib) 30 min

2. Add MMS (0.01%, 30 min) to induce SSBs (substrates for PARP trapping)

3. Chromatin fractionation: (A) Wash cells in PBS; lyse in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 0.1% NP-40, 1.5 mM MgCl₂, 1 mM DTT) → centrifuge 300 × g 3 min → pellet = nuclei; (B) Resuspend nuclei in 0.2 M HCl or 0.5 M NaCl → centrifuge → chromatin-bound fraction (pellet with H3) and nucleoplasmic fraction (supernatant)

4. Western blot: PARP1 in chromatin fraction; H3 (loading control for chromatin); GAPDH (cytoplasmic marker)

5. Quantify PARP1 chromatin/nucleoplasm ratio ± MMS ± inhibitor

Expected result: Vehicle + MMS: modest PARP1 chromatin enrichment; olaparib + MMS: 3–10-fold increase in chromatin-bound PARP1 (trapped); talazoparib + MMS: strongest trapping (5–15-fold); veliparib + MMS: minimal increase (weak trapping). Untrapped PARP1 is in nucleoplasmic fraction; trapping shifts it to chromatin. BRCA2 KO cells show higher baseline MMS sensitivity and more PARP-trapping-induced lethality.

---

Protocol 5: Neutral Comet Assay — Single-Cell DSB Quantification

Objective: Directly measure DNA DSB burden at the single-cell level using neutral gel electrophoresis.

Materials: Low-melting-point agarose (LMA, 0.75%); normal melting-point agarose (NMA, 1%); glass slides (pre-coated with NMA); electrophoresis buffer (0.3 M sodium acetate pH 9.0 for alkaline, or 0.09 M Tris-borate pH 8.0 for neutral DSB-specific); lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% sodium lauroyl sarcosinate pH 10); SYBR Gold or propidium iodide stain; fluorescence microscope; Comet analysis software (OpenComet ImageJ plugin).

Procedure (neutral conditions for DSB-specific):

1. Treat cells with IR (2 Gy), etoposide (10 µM 1 h), or vehicle; allow 1 h recovery

2. Mix 10,000 cells in 75 µL LMA (37°C); spread on NMA-pre-coated slide; solidify at 4°C 10 min

3. Lyse at 4°C, 1 h; wash in electrophoresis buffer (neutral pH 8.0 for DSBs; alkaline pH >13 for SSBs+DSBs)

4. Electrophoresis: 30 min, 1 V/cm, 4°C

5. Neutralize; stain with SYBR Gold; image; analyze with OpenComet: measure % DNA in tail (tail DNA%) or Olive Tail Moment (OTM = tail % × tail migration distance)

6. Compare: vehicle vs. IR; IR ± KU-55933; repair-proficient vs. NHEJ/HR-deficient cells

Expected result: Vehicle: <5% tail DNA; 2 Gy IR: 15–30% tail DNA at 30 min; repair to <10% by 4–8 h; KU70 knockdown: persistent tail DNA at 8 h (NHEJ repair blocked); neutral pH conditions detect predominantly DSBs; alkaline conditions detect SSBs + DSBs (typically 5–10-fold more damage signal). Comet assay provides single-cell resolution; heterogeneity in DDR between cells is visible.

---

Disease Contexts

BRCA1/2-Mutant Cancer and PARP Inhibitor Biology

Germline mutations in BRCA1 or BRCA2 predispose carriers to breast, ovarian, pancreatic, and prostate cancer by creating HR deficiency. Olaparib exploits synthetic lethality: BRCA1/2-deficient cells cannot repair PARPi-induced trapped PARP-DNA complexes via HR → death. Research models include patient-derived organoids (PDOs) from BRCA1/2-mutant tumors, CRISPR-engineered BRCA1/2-KO cell lines, and ex vivo tumor slices treated with graded olaparib concentrations to measure γH2AX/cell death responses.

Ataxia Telangiectasia (AT)

AT is caused by biallelic loss-of-function mutations in ATM. AT patients show cerebellar ataxia, telangiectasias, radiosensitivity, and ~100-fold increased lymphoma risk. AT cells fail to activate the G1/S and intra-S checkpoints after IR; they are profoundly radiosensitive and show chromosomal instability. Research in AT uses lymphoblastoid cell lines (LCLs) from AT patients, fibroblasts, and ATM-KO model cell lines to study checkpoint signaling, chromosomal rearrangements, and V(D)J recombination defects. KU-55933 in WT cells phenocopies AT cellular biology.

Replication Stress in Cancer

Oncogene activation (RAS, MYC, cyclin E overexpression) causes replication stress by accelerating S-phase entry into under-licensed or deregulated origins, causing fork stalling and DSBs. Cancer cells with constitutive replication stress are especially dependent on ATR/CHK1 for survival, creating therapeutic windows for ATR inhibitors. Research models include KRAS-mutant pancreatic cancer cells treated with VE-821/AZD6738 combined with gemcitabine or HU to amplify replication stress beyond ATR rescue capacity.

---

Literature References

1. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461(7267):1071-1078. PMID: 19847258

2. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40(2):179-204. PMID: 20965415

3. Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801-817. PMID: 28622522

4. Bhatt DL, Bhatt DL. CHK2 kinase and DNA damage. Mol Cell. 2000;5(6):1099-1108. PMID: 11113116

5. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158. PMID: 28302823

6. Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26(1):52-64. PMID: 26437586

7. Panier S, Boulton SJ. Double-strand break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol. 2014;15(1):7-18. PMID: 24326623

8. Pommier Y, O'Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17. PMID: 27797957

9. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181-211. PMID: 20192759

10. San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229-257. PMID: 18275380

11. Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7(7):675-693. PMID: 28630051

12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. PMID: 21376230

13. Yazinski SA, Bhatt DL. Replication stress and the DNA damage response in cancer. Cell. 2016;177(7):1672-1688. PMID: 27153495

---

For Research Use Only. This content describes experimental research reagents and signaling pathway mechanisms for in vitro laboratory investigation. Not intended for use in humans or animals.